Siemens Healthineers (OTCMKTS:SMMNY) Upgraded at Zacks Research

Siemens Healthineers (OTCMKTS:SMMNY) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

Siemens Healthineers Stock Performance

SMMNY stock opened at $22.81 on Thursday. Siemens Healthineers has a 1-year low of $19.20 and a 1-year high of $28.92. The business has a fifty day moving average price of $20.20 and a 200-day moving average price of $21.66.

Siemens Healthineers (OTCMKTS:SMMNY) last issued its earnings results on Thursday, May 7th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.29 by $0.02. The business had revenue of $6.68 billion during the quarter, compared to analysts’ expectations of $6.96 billion.

About Siemens Healthineers

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.